News >

Avelumab Falls Short in Phase III NSCLC Trial

Jason Harris
Published: Thursday, Feb 15, 2018

Fabrice Barlesi, MD

Fabrice Barlesi, MD
Avelumab (Bavencio) missed the primary endpoint of improving overall survival (OS) in pretreated patients with non–small cell lung cancer (NSCLC), according to findings from the phase III JAVELIN Lung 200 Trial.1

Avelumab currently has FDA approved indications for the treatment of patients with Merkel cell carcinoma and urothelial carcinoma.


  1. Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Merck. Published February 15, 2018. Accessed February 15, 2018.
  2. Jerusalem G, Chen FL, Spigel D, et al. JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC. Presented at: 17th World Lung Cancer Conference, the Annual Meeting of the International Association for the Study of Lung Cancer (IASLC); December 4-7, 2016; Vienna, Austria.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication